CHICAGO , Dec. 12, 2024 /PRNewswire/ -- Green Courte Partners, LLC ("GCP"), a private equity real estate investment firm focused on building industry-leading companies within niche real estate sectors, announced today that its sixth investment fund, Green Courte Real Estate Partners VI, LLC and its affiliates, acquired Cottages of Monroe , a 51-unit active-adult cottage community located in Monroe, Georgia , just east of Atlanta . The acquisition increases GCP's national senior living portfolio, which is managed by the firm's wholly owned operating platform, True Connection Communities, to 20 communities containing approximately 3,200 units. www.GreenCourtePartners.com for more information. (PRNewsfoto/Green Courte Partners, LLC)" alt="Green Courte Partners, LLC Logo. Please visit www.GreenCourtePartners.com for more information. (PRNewsfoto/Green Courte Partners, LLC)"> Matt Pyzyk , Managing Director at GCP, said, "We are excited to expand our portfolio and enter the Atlanta market with the acquisition of Cottages of Monroe , which has earned a strong local reputation and consistently maintained high occupancy rates. This gated community has been a key target for us due to its attractive location and the desirability of its single-story cottage product. With this acquisition, our senior living portfolio now includes approximately 650 cottages. We are actively pursuing opportunities to acquire or develop similar communities to expand our senior cottage portfolio." Randy Griffin , one of Green Courte's counterparties in the transaction, added, "We've had a long-standing relationship with GCP. They approached us directly and were able to structure a deal that accomplished our objectives. We were pleased with the timeline and outcome of the transaction." About Green Courte Partners, LLC Green Courte Partners, LLC is a Chicago -based private equity real estate investment firm focused on building industry-leading companies within niche real estate sectors. The firm has active investments in the following sectors: active-adult/independent senior living, land-lease communities, industrial outdoor storage, and near-airport parking. The firm combines focused investment strategies with a disciplined approach to transaction execution, operations, and asset management. Green Courte's goal is to invest in high-quality real estate assets that will generate attractive risk-adjusted returns over a long-term holding period. For additional information, please visit Green Courte's website at www.GreenCourtePartners.com . About True Connection Communities True Connection Communities operates a high-quality portfolio of 20 active-adult and independent senior living communities, containing approximately 3,200 units located in 11 states, to meet the growing needs of Americans over the age of 55 seeking an active and engaged lifestyle. To deliver an exceptional resident experience, the company focuses on five key offerings: custom-designed fitness and wellness programs, creative chef-prepared meals made with the freshest seasonal ingredients, social activities designed for a life on the move, innovative educational programs, and state-of-the-art technology. To learn more, visit www.TrueConnectionCommunities.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/green-courte-partners-acquires-active-adult-community-located-in-atlanta-georgia-msa-302330844.html SOURCE Green Courte Partners, LLC © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.In conclusion, the decision by Manchester United to abolish the role of a sporting director following the dismissal of John Ashworth has sent shockwaves through the football world. With Ashworth now linked to a potential move to Arsenal, the rivalry between the two clubs takes on a new dimension, adding intrigue and suspense to an already captivating narrative. Only time will tell how these developments will shape the future of both clubs and English football as a whole.

In a battle of underdogs, Sheriff Tiraspol face off against Shakhtar Donetsk in what promises to be an intriguing contest. Can the Moldovan champions cause an upset against the Ukrainian giants, or will Shakhtar assert their dominance?

Luigi Mangione defense fund raises more than $55,000 in donations

Title: The Story Unveiled: Brother Seeks to Uncover What His Sister Has Been Through in the Last 13 YearsTHOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen

Stock Music Market to Grow by USD 650.4 Million from 2023-2028, Report on AI Redefining Market Landscape - TechnavioDuck Creek partners with Suncorp to deliver a suite of cloud-native, low-code core insurance delivery solutions6. Atletico Madrid vs. Porto:

European football: Kane hits hat-trick for leaders Bayern as PSG cruise

Dunhuang, Sanxingdui Featured on Alipay Cultural Skins, Emerging as Must-Have Items for Young People Seeking Good LuckInvestors wondering if the presidential election may usher in a bad or good time for the stock market won’t find any easy answers looking at the past. One year after President Joe Biden won the presidency in 2020, the S&P 500 was up more than 42%, according to data provided to CNBC by Morningstar Direct. (Morningstar analyzed the returns in the six and 12 months following Election Day for those 24 U.S. presidential elections.) The index fell around 6% in the 12 months after Jimmy Carter defeated former Republican President Gerald Ford. It dropped a similar amount in the year following Dwight Eisenhower’s second win. Meanwhile, a year after Ronald Reagan was first elected, the S&P 500 was up 0.6%. Twelve months after Reagan’s reelection, the index had swelled around 19%. When you look at how stocks fare after presidential elections, “there’s no obvious and discernible pattern,” said Jude Boudreaux, a certified financial planner who is a partner with The Planning Center in New Orleans. “Election years aren’t that different from a typical year in the stock market,” said Boudreaux, a member of the CNBC FA Council . In other words, the market’s movements are just as unpredictable. As a result, Boudreaux said he isn’t recommending any broad changes for clients based on President-elect Donald Trump ’s win. Dan Kemp, global chief investment officer for Morningstar Investment Management, had similar advice to investors. “When investors face uncertainty, they might seek narratives that predict the future and then change their portfolios accordingly,” Kemp said in a statement. But, he said, “the most important thing an investor can do is stick to their plan.”

As Xiaohongshu continues to evolve and grow, the establishment of the Application Algorithm Department marks a pivotal moment in its journey towards becoming a leading force in the social media and e-commerce space. With Xiaohou at the helm, the department is poised to drive innovation and set new standards for algorithmic excellence, setting the stage for an exciting future ahead for Xiaohongshu and its millions of users worldwide.Surface Inspection Market: Surface Inspection Market to Grow to USD 10.29B by 2031 12-02-2024 09:21 PM CET | Industry, Real Estate & Construction Press release from: SkyQuest Technology Surface Inspection Market Scope: Key Insights : Surface Inspection Market size was valued at USD 5.02 billion in 2022 and is poised to grow from USD 5.44 billion in 2023 to USD 10.29 billion by 2031, growing at a CAGR of 8.3% in the forecast period (2024-2031). Discover Your Competitive Edge with a Free Sample Report : https://www.skyquestt.com/sample-request/surface-inspection-market Access the full 2024 Market report for a comprehensive understanding @ https://www.skyquestt.com/report/surface-inspection-market In-Depth Exploration of the global Surface Inspection Market: This report offers a thorough exploration of the global Surface Inspection market, presenting a wealth of data that has been meticulously researched and analyzed. It identifies and examines the crucial market drivers, including pricing strategies, competitive landscapes, market dynamics, and regional growth trends. By outlining how these factors impact overall market performance, the report provides invaluable insights for stakeholders looking to navigate this complex terrain. Additionally, it features comprehensive profiles of leading market players, detailing essential metrics such as production capabilities, revenue streams, market value, volume, market share, and anticipated growth rates. This report serves as a vital resource for businesses seeking to make informed decisions in a rapidly evolving market. Trends and Insights Leading to Growth Opportunities The best insights for investment decisions stem from understanding major market trends, which simplify the decision-making process for potential investors. The research strives to discover multiple growth opportunities that readers can evaluate and potentially capitalize on, armed with all relevant data. Through a comprehensive assessment of important growth factors, including pricing, production, profit margins, and the value chain, market growth can be more accurately forecast for the upcoming years. Top Firms Evaluated in the Global Surface Inspection Market Research Report: Cognex Corporation (US) Omron Corporation (Japan) Keyence Corporation (Japan) Basler AG (Germany) Teledyne Technologies Incorporated (US) Baumer Holding AG (Switzerland) JAI A/S (Denmark) National Instruments Corporation (US) Panasonic Corporation (Japan) SICK AG (Germany) Key Aspects of the Report: Market Summary: The report includes an overview of products/services, emphasizing the global Surface Inspection market's overall size. It provides a summary of the segmentation analysis, focusing on product/service types, applications, and regional categories, along with revenue and sales forecasts. Competitive Analysis: This segment presents information on market trends and conditions, analyzing various manufacturers. It includes data regarding average prices, as well as revenue and sales distributions for individual players in the market. Business Profiles: This chapter provides a thorough examination of the financial and strategic data for leading players in the global Surface Inspection market, covering product/service descriptions, portfolios, geographic reach, and revenue divisions. Sales Analysis by Region: This section provides data on market performance, detailing revenue, sales, and market share across regions. It also includes projections for sales growth rates and pricing strategies for each regional market, such as: North America: United States, Canada, and Mexico Europe: Germany, France, UK, Russia, and Italy Asia-Pacific: China, Japan, Korea, India, and Southeast Asia South America: Brazil, Argentina, Colombia, etc. Middle East and Africa: Saudi Arabia, UAE, Egypt, Nigeria, and South Africa This in-depth research study has the capability to tackle a range of significant questions that are pivotal for understanding the market dynamics, and it specifically aims to answer the following key inquiries: How big could the global Surface Inspection market become by the end of the forecast period? Let's explore the exciting possibilities! Will the current market leader in the global Surface Inspection segment continue to hold its ground, or is change on the horizon? Which regions are poised to experience the most explosive growth in the Surface Inspection market? Discover where the future opportunities lie! Is there a particular player that stands out as the dominant force in the global Surface Inspection market? Let's find out who's leading the charge! What are the key factors driving growth and the challenges holding back the global Surface Inspection market? Join us as we uncover the forces at play! To establish the important thing traits, Ask Our Experts @ https://www.skyquestt.com/speak-with-analyst/surface-inspection-market Table of Contents Chapter 1 Industry Overview 1.1 Definition 1.2 Assumptions 1.3 Research Scope 1.4 Market Analysis by Regions 1.5 Market Size Analysis from 2023 to 2030 11.6 COVID-19 Outbreak: Medical Computer Cart Industry Impact Chapter 2 Competition by Types, Applications, and Top Regions and Countries 2.1 Market (Volume and Value) by Type 2.3 Market (Volume and Value) by Regions Chapter 3 Production Market Analysis 3.1 Worldwide Production Market Analysis 3.2 Regional Production Market Analysis Chapter 4 Medical Computer Cart Sales, Consumption, Export, Import by Regions (2023-2023) Chapter 5 North America Market Analysis Chapter 6 East Asia Market Analysis Chapter 7 Europe Market Analysis Chapter 8 South Asia Market Analysis Chapter 9 Southeast Asia Market Analysis Chapter 10 Middle East Market Analysis Chapter 11 Africa Market Analysis Chapter 12 Oceania Market Analysis Chapter 13 Latin America Market Analysis Chapter 14 Company Profiles and Key Figures in Medical Computer Cart Business Chapter 15 Market Forecast (2023-2030) Chapter 16 Conclusions Address: 1 Apache Way, Westford, Massachusetts 01886 Phone: USA (+1) 351-333-4748 Email: sales@skyquestt.com About Us: SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally. This release was published on openPR.